(oks i METH oh lone)
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Anadrol-50: 50 mg [scored]
Brand Names: U.S.
- Anabolic Steroid
Enhances production of erythropoietin in patients with anemias which are due to bone marrow failure; stimulates erythropoiesis in anemias due to deficient red cell production
Onset of Action
Response is not often immediate; a minimum trial of 3 to 6 months is recommended
Use: Labeled Indications
Treatment of anemias caused by deficient red cell production
Hypersensitivity to oxymetholone or any component of the formulation; breast cancer in men; breast cancer in women with hypercalcemia; prostate cancer; severe hepatic dysfunction; nephrosis or nephrotic phase of nephritis; pregnancy or use in women who may become pregnant
Note: The National Kidney Foundation does not recommend the use of androgens as an adjuvant to ESA treatment in anemic patients with chronic kidney disease (KDOQI, 2006).
Erythropoietic effects: Oral: 1-5 mg/kg/day once daily; usual effective dose: 1-2 mg/kg/day; give for a minimum trial of 3-6 months because response may be delayed
Refer to adult dosing.
Refer to adult dosing.
Dosing: Renal Impairment
No dosage adjustment provided in manufacturer’s labeling. Use with caution due to risk of edema in patients with renal impairment.
Dosing: Hepatic Impairment
Mild to moderate impairment: There are no dosage adjustments provided in the manufacturer’s labeling.
Severe impairment: Use is contraindicated.
Store at room temperature 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Protect from light.
Blood Glucose Lowering Agents: Androgens may enhance the hypoglycemic effect of Blood Glucose Lowering Agents. Monitor therapy
C1 inhibitors: Androgens may enhance the thrombogenic effect of C1 inhibitors. Monitor therapy
Corticosteroids (Systemic): May enhance the fluid-retaining effect of Androgens. Monitor therapy
CycloSPORINE (Systemic): Androgens may enhance the hepatotoxic effect of CycloSPORINE (Systemic). Androgens may increase the serum concentration of CycloSPORINE (Systemic). Consider therapy modification
Vitamin K Antagonists (eg, warfarin): Androgens may enhance the anticoagulant effect of Vitamin K Antagonists. Consider therapy modification
Decreased thyroxine-binding globulin, T4; increased resin uptake of T3 and T4
Frequency not defined.
Cardiovascular: Coronary artery disease, peripheral edema
Central nervous system: Chills, excitation, insomnia
Dermatologic: Acne, hirsutism (women), hyperpigmentation, male-pattern baldness (postpubertal males, women)
Endocrine & metabolic: Amenorrhea, clitoromegaly, glucose tolerance decreased, gynecomastia, HDL-cholesterol decreased, hypercalcemia, hyperchloremia, hyperkalemia, hypernatremia, hyperphosphatemia, LDL-cholesterol increased, libido increased/decreased, menstrual irregularities, virilism (women)
Gastrointestinal: Diarrhea, nausea, vomiting
Genitourinary: Bladder irritability, epididymitis, impotence, oligospermia, penile enlargement, penile erections increased (prepubertal males), priapism, prostate cancer, prostatic hyperplasia (elderly males), seminal volume decreased, testicular atrophy, testicular dysfunction
Hematologic: Bleeding, INR increased, iron-deficiency anemia, leukemia, prothrombin time increased, clotting factors (II, V, VII, X) suppressed
Hepatic: Alkaline phosphatase increased, bilirubin increased, cholestatic hepatitis, cholestatic jaundice, hepatic failure, hepatic necrosis, hepatocellular carcinoma, liver cell tumors, peliosis hepatis, transaminases increased
Neuromuscular & skeletal: Creatine phosphokinase increased, premature closure of epiphysis (children)
Renal: Creatinine increased
Respiratory: Hoarseness (women)
Miscellaneous: Voice deepening (women)
Postmarketing and/or case reports (Limited to important or life-threatening): Hepatotoxicity (idiosyncratic) (Chalasani, 2014)
Concerns related to adverse effects:
• Blood lipid changes: [U.S. Boxed Warning]: Anabolic steroids may cause changes in blood lipids (decreased high density lipoproteins and sometimes increased low density lipoproteins), increasing the risk of arteriosclerosis and coronary artery disease.
• Clotting factor alterations: Anabolic steroids may suppress factors II, V, VII, and X; prothrombin time may be increased.
• Hepatic effects: [U.S. Boxed Warning]: Androgenic anabolic steroid treatment may cause peliosis hepatis, which occurs when splenic or hepatic tissue is replaced by cysts (blood-filled); may only cause minimal hepatic dysfunction although has been associated with hepatic failure. Androgenic liver cell tumors, which may be benign, although malignant tumors have also been reported; generally regress when anabolic steroid treatment is withdrawn. Both conditions (peliosis and tumors) may not be apparent until liver failure or intra-abdominal hemorrhage develops. Androgen use (low doses) has also been associated with cholestatic hepatitis and jaundice; may be associated with hepatomegaly and right upper-quadrant pain; jaundice is typically reversible upon discontinuation (continuing treatment has been associated with coma and death). Monitor liver function periodically.
• Prostate conditions: Androgenic anabolic steroid use may cause prostatic hypertrophy or prostate cancer in elderly men.
• Breast cancer: May cause hypercalcemia in women with breast cancer by stimulating osteolysis.
• Diabetes: Use with caution in patients with diabetes mellitus; insulin or oral hypoglycemic needs may be altered; monitor carefully.
• Edematous conditions: Use with caution in patients with conditions influenced by edema (eg, cardiovascular disease, migraine, seizure disorder, renal impairment); may cause fluid retention.
• Pediatric: May accelerate bone maturation without producing compensatory gain in linear growth in children; effect may continue for 6 months after treatment discontinuation; in prepubertal children perform radiographic examination of the hand and wrist every 6 months to determine the rate of bone maturation and to assess the effect of treatment on the epiphyseal centers.
• Women: Discontinue with evidence of mild virilization in women.
• Appropriate use: Oxymetholone should not replace other anemia treatment supportive measures such as transfusion, correction of iron, folic acid, vitamin B12 or pyridoxine deficiency, antibacterial therapy, and the appropriate use of corticosteroids.
Periodic liver function tests, lipid profile, hemoglobin and hematocrit; iron studies; serum glucose (may be decreased by testosterone, monitor patients with diabetes); radiologic examination of bones every 6 months (when using in prepubertal children); monitor urine and serum calcium and signs of virilization in women treated for breast cancer
Pregnancy Risk Factor
Oligospermia or amenorrhea may occur resulting in an impairment of fertility. Use is contraindicated in women who are or may become pregnant.
• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)
• Patient may experience diarrhea, insomnia, or sexual dysfunction. Have patient report immediately to prescriber signs of liver problems (dark urine, feeling tired, lack of appetite, nausea, abdominal pain, light-colored stools, vomiting, or yellow skin or eyes), priapism, acne, shortness of breath, excessive weight gain, swelling of arms or legs, urinary retention, change in amount of urine passed, muscle weakness, bruising, bleeding, severe anxiety, or signs of virilization (in females a deep voice, facial hair, pimples, or period changes) (HCAHPS).
• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.
Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for healthcare professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience and judgment in diagnosing, treating and advising patients.